USO 19151
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) STAR
Disease Types: Solid Tumors Research
Eligibility Requirements:
-NSCLC (squamous or non-squamous; mixed histology not allowed) or colorectal solid tumors with KRAS G12c mutations
-must have unresectable or metastatic disease with no standard of care treatment options available
-NSCLC patients must have had platinum based chemotherapy & treatment with a check point inhibitor
-no active brain metastasis, carcinomatous meningitis, significant hemoptysis or hemorrhage within last 4 weeks, GI condition or disease that prevents absorption of oral medication, significant heart disease, history of stroke or TIA within last 6 months, or known HIV, active Hep B or Hep C
Available at: